1079 related articles for article (PubMed ID: 25925381)
1. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
2. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
3. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
4. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
5. Reporting tumor molecular heterogeneity in histopathological diagnosis.
Mafficini A; Amato E; Fassan M; Simbolo M; Antonello D; Vicentini C; Scardoni M; Bersani S; Gottardi M; Rusev B; Malpeli G; Corbo V; Barbi S; Sikora KO; Lawlor RT; Tortora G; Scarpa A
PLoS One; 2014; 9(8):e104979. PubMed ID: 25127237
[TBL] [Abstract][Full Text] [Related]
6. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
8. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
Muller E; Brault B; Holmes A; Legros A; Jeannot E; Campitelli M; Rousselin A; Goardon N; Frébourg T; Krieger S; Crouet H; Nicolas A; Sastre X; Vaur D; Castéra L
Cancer Med; 2015 Oct; 4(10):1484-93. PubMed ID: 26155992
[TBL] [Abstract][Full Text] [Related]
9. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
10. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Gailey MP; Stence AA; Jensen CS; Ma D
Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
[TBL] [Abstract][Full Text] [Related]
11. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
[TBL] [Abstract][Full Text] [Related]
12. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G; Grassini G; Bartocci P; Francaviglia I; Dal Cin E; Barbieri G; Arrigoni G; Pecciarini L; Doglioni C; Cangi MG
Oncotarget; 2015 Oct; 6(31):30592-603. PubMed ID: 26435479
[TBL] [Abstract][Full Text] [Related]
13. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
[TBL] [Abstract][Full Text] [Related]
14. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
15. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
17. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
18. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
[TBL] [Abstract][Full Text] [Related]
19. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
